See more : Shenzhen Goodix Technology Co., Ltd. (603160.SS) Income Statement Analysis – Financial Results
Complete financial analysis of NightHawk Biosciences, Inc. (NHWK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NightHawk Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shanxi Lanhua Sci-Tech Venture Co.,Ltd (600123.SS) Income Statement Analysis – Financial Results
- Diversified Energy Company PLC (DEC.L) Income Statement Analysis – Financial Results
- Poolia AB (publ) (POOL-B.ST) Income Statement Analysis – Financial Results
- Lanna Resources Public Company Limited (LANNA.BK) Income Statement Analysis – Financial Results
- Round One Corporation (RNDOF) Income Statement Analysis – Financial Results
NightHawk Biosciences, Inc. (NHWK)
About NightHawk Biosciences, Inc.
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.98M | 2.11M | 2.95M | 3.05M | 5.79M | 1.52M | 341.64K | 0.00 | 0.00 | 0.00 | 3.11K | 187.79K |
| Cost of Revenue | 6.40M | 691.48K | 12.94M | 13.01M | 16.23M | 8.27M | 9.33M | 116.00K | 5.25M | 1.40M | 253.19K | 0.00 |
| Gross Profit | -420.03K | 1.42M | -9.99M | -9.96M | -10.44M | -6.75M | -8.99M | -116.00K | -5.25M | -1.40M | -250.08K | 187.79K |
| Gross Profit Ratio | -7.02% | 67.27% | -338.91% | -326.80% | -180.18% | -443.94% | -2,631.12% | 0.00% | 0.00% | 0.00% | -8,041.13% | 100.00% |
| Research & Development | 23.46M | 18.82M | 12.94M | 13.01M | 16.23M | 8.27M | 9.33M | 2.60M | 2.86M | 2.74M | 902.94K | 1.25M |
| General & Administrative | 21.13M | 16.83M | 14.93M | 9.43M | 7.03M | 6.37B | 4.14M | 4.36M | 3.98M | 2.43B | 1.18M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.36B | 0.00 | 14.07M | 5.35M | -2.43B | 5.92K | 0.00 |
| SG&A | 21.13M | 16.83M | 14.93M | 9.43M | 7.03M | 6.37M | 4.14M | 18.43M | 9.33M | 3.83M | 1.44M | 976.00K |
| Other Expenses | 628.45K | -965.82K | 188.42K | -25.56K | 117.78K | 224.29M | 670.78K | 14.07M | 5.35M | 1.40B | 0.00 | 0.00 |
| Operating Expenses | 45.22M | 35.65M | 27.87M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Cost & Expenses | 51.62M | 35.65M | 27.87M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Interest Income | 987.25K | 815.32K | 566.72K | 431.82K | 265.75K | 22.17K | 31.14K | 66.00K | 40.57K | 10.07K | 2.00 | 517.00 |
| Interest Expense | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 549.40K | 364.00K | 73.35K | 79.12K | 101.09K | 63.17K |
| Depreciation & Amortization | 4.93M | 4.35M | 3.74M | 2.70M | 237.32K | 134.08K | 132.08K | 116.00K | 66.90K | 6.35K | 2.59K | 624.00 |
| EBITDA | -40.76M | -31.07M | -22.38M | -18.05M | -16.73M | -12.96M | -12.29M | -20.84M | -12.08M | -6.55M | -2.34M | -2.03M |
| EBITDA Ratio | -681.44% | -1,470.53% | -759.20% | -591.82% | -288.77% | -852.82% | -3,598.29% | 0.00% | 0.00% | 0.00% | -75,243.99% | -1,082.96% |
| Operating Income | -45.69M | -35.42M | -26.12M | -20.75M | -17.96M | -13.34M | -13.13M | -21.02M | -12.19M | -6.56M | -2.34M | -2.03M |
| Operating Income Ratio | -763.90% | -1,676.40% | -886.18% | -680.39% | -309.99% | -877.85% | -3,842.41% | 0.00% | 0.00% | 0.00% | -75,327.23% | -1,083.57% |
| Total Other Income/Expenses | -1.51M | -4.38M | -1.46M | -944.02K | -112.40K | -700.85K | 152.52K | -100.00K | -56.00K | -45.22K | -108.34K | -64.18K |
| Income Before Tax | -47.15M | -35.55M | -26.38M | -20.34M | -17.58M | -13.22M | -12.97M | -21.12M | -12.24M | -6.61M | -2.45M | -2.10M |
| Income Before Tax Ratio | -788.35% | -1,682.44% | -894.90% | -667.07% | -303.37% | -869.73% | -3,797.77% | 0.00% | 0.00% | 0.00% | -78,810.87% | -1,117.75% |
| Income Tax Expense | -3.29M | -145.97K | 1.31M | 45.18K | -985.49K | -809.54K | 819.34K | -463.00K | -381.04K | 2.18M | 70.27K | 69.08K |
| Net Income | -43.86M | -35.40M | -27.69M | -20.38M | -15.73M | -11.84M | -12.57M | -20.30M | -11.79M | -8.71M | -2.42M | -2.10M |
| Net Income Ratio | -733.36% | -1,675.54% | -939.43% | -668.55% | -271.56% | -779.09% | -3,680.44% | 0.00% | 0.00% | 0.00% | -77,819.94% | -1,120.89% |
| EPS | -1.72 | -1.42 | -1.73 | -4.29 | -6.30 | -21.56 | -50.05 | -177.23 | -127.84 | -162.73 | -92.49 | -79.03 |
| EPS Diluted | -1.71 | -1.42 | -1.73 | -4.29 | -6.30 | -21.56 | -50.05 | -174.92 | -126.18 | -160.61 | -91.28 | -79.03 |
| Weighted Avg Shares Out | 25.55M | 24.87M | 15.98M | 4.75M | 2.50M | 549.33K | 251.23K | 114.51K | 92.21K | 53.53K | 26.17K | 26.63K |
| Weighted Avg Shares Out (Dil) | 25.61M | 24.91M | 15.98M | 4.75M | 2.50M | 549.33K | 251.23K | 116.02K | 93.43K | 54.24K | 26.51K | 26.63K |
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
Source: https://incomestatements.info
Category: Stock Reports